Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 23 August, 2007

XTL Biopharm Ltd

PDMR Shareholding


   NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL   
                      RESPONSIBILITY OR CONNECTED PERSONS                      

Valley Cottage, New York, August 23, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) received notification on 21 August 2007
from the Company's officers as follows:

  * Ron Bentsur, the Company's CEO, purchased a total of 15,279 American
    Depositary Receipts ("ADRs") (representing 152,790 ordinary shares, being
    less than 0.1 per cent of the issued share capital) at an average price of
    $1.30 per ADR on August 21, 2007. This brings his direct holdings up to
    20,101 ADRs, representing 201,010 ordinary shares, being less than 0.1 per
    cent of the issued share capital; and
   
  * Bill Kessler, the Company's Director of Finance, purchased a total of 5,000
    ADRs (representing 50,000 ordinary shares, being less than 0.1 per cent of
    the issued share capital) at an average price of $1.29 per ADR on August
    21, 2007. This brings his direct holdings up to 5,000 ADRs, representing
    50,000 ordinary shares, being less than 0.1 per cent of the issued share
    capital.
   
Each ADR represents 10 ordinary shares of the Company.

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225

+972-8-930-4444


                                                                                                                                                                                

a d v e r t i s e m e n t